Neuroprotective Potential of Hesperidin as Therapeutic Agent in
the Treatment of Brain Disorders: Preclinical Evidence-based
Review

Keshav      Bansal; Vanshita      Singh; Sakshi      Singh; Samiksha      Mishra

doi:10.2174/1566524023666230320144722

Abstract

Neurodegenerative disorders (NDs) are progressive morbidities that represent a serious health issue in the aging world population. There is a contemporary upsurge in worldwide interest in the area of traditional remedies and phytomedicines are widely accepted by researchers due to their health-promoted effects and fewer side effects. Hesperidin, a flavanone glycoside present in the peels of citrus fruits, possesses various biological activities including anti-inflammatory and antioxidant actions. In various preclinical studies, hesperidin has provided significant protective actions in a variety of brain disorders such as Alzheimer’s disease, epilepsy, Parkinson’s disease, multiple sclerosis, depression, neuropathic pain, etc. as well as their underlying mechanisms. The findings indicate that the neuroprotective effects of hesperidin are mediated by modulating antioxidant defence activities and neural growth factors, diminishing apoptotic and neuro-inflammatory pathways. This review focuses on the potential role of hesperidin in managing and treating diverse brain disorders.

Keywords: Hesperidin, flavonoid, neuroprotection, epilepsy, Alzheimer’s disease, Parkinson’s disease.

« Previous Next »

[1]
Gao HM, Hong JS. Why neurodegenerative diseases are progressive: Uncontrolled inflammation drives disease progression. Trends Immunol  2008; 29(8): 357-65.
 [http://dx.doi.org/10.1016/j.it.2008.05.002] [PMID:  18599350]

[2]
Uttara B, Singh A, Zamboni P, Mahajan R. Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol  2009; 7(1): 65-74.
 [http://dx.doi.org/10.2174/157015909787602823] [PMID:  19721819]

[3]
Kovacs GG. Concepts and classification of neurodegenerative diseases. Handb Clin Neurol  2018; 145: 301-7.
 [http://dx.doi.org/10.1016/B978-0-12-802395-2.00021-3] [PMID:  28987178]

[4]
Zhou J, Gennatas ED, Kramer JH, Miller BL, Seeley WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron  2012; 73(6): 1216-27.
 [http://dx.doi.org/10.1016/j.neuron.2012.03.004] [PMID:  22445348]

[5]
Fu H, Hardy J, Duff KE. Selective vulnerability in neurodegenerative diseases. Nat Neurosci  2018; 21(10): 1350-8.
 [http://dx.doi.org/10.1038/s41593-018-0221-2] [PMID:  30250262]

[6]
Das SK, Ray BK, Paul N, et al. Prevalence, burden, and risk factors of migraine: A community-based study from Eastern India. Neurol India  2017; 65(6): 1280-8.
 [http://dx.doi.org/10.4103/0028-3886.217979] [PMID:  29133701]

[7]
Mishra A, Bandopadhyay R, Singh PK, Mishra PS, Sharma N, Khurana N. Neuroinflammation in neurological disorders: Pharmacotherapeutic targets from bench to bedside. Metab Brain Dis  2021; 36(7): 1591-626.
 [http://dx.doi.org/10.1007/s11011-021-00806-4] [PMID:  34387831]

[8]
Dhingra A, Chopra B, Bonthagarala B. Natural anti-inflammatory agents: Recent progress and future perspectives. Ann Pharmacol Pharm  2018; 3(5): 1158.

[9]
Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol Ther  2002; 96(2-3): 67-202.
 [http://dx.doi.org/10.1016/S0163-7258(02)00298-X] [PMID:  12453566]

[10]
Maan G, Sikdar B, Kumar A, Shukla R, Mishra A. Role of flavonoids in neurodegenerative diseases: Limitations and future perspectives. Curr Top Med Chem  2020; 20(13): 1169-94.
 [http://dx.doi.org/10.2174/1568026620666200416085330] [PMID:  32297582]

[11]
Maher P. The potential of flavonoids for the treatment of neurodegenerative diseases. Int J Mol Sci  2019; 20(12): 3056.
 [http://dx.doi.org/10.3390/ijms20123056] [PMID:  31234550]

[12]
Ko YH, Kim SK, Lee SY, Jang CG. Flavonoids as therapeutic candidates for emotional disorders such as anxiety and depression. Arch Pharm Res  2020; 43(11): 1128-43.
 [http://dx.doi.org/10.1007/s12272-020-01292-5] [PMID:  33225387]

[13]
Mishra A, Goel RK. Chronic 5-HT3 receptor antagonism ameliorates seizures and associated memory deficit in pentylenetetrazole-kindled mice. Neuroscience  2016; 339: 319-28.
 [http://dx.doi.org/10.1016/j.neuroscience.2016.10.010] [PMID:  27746348]

[14]
Li C, Schluesener H. Health-promoting effects of the citrus flavanone hesperidin. Crit Rev Food Sci Nutr  2017; 57(3): 613-31.
 [http://dx.doi.org/10.1080/10408398.2014.906382] [PMID:  25675136]

[15]
Suzuki H, Asakawa A, Kawamura N, Yagi T, Inui A. Hesperidin potentiates ghrelin signaling. Recent Pat Food Nutr Agric  2014; 6(1): 60-3.
 [http://dx.doi.org/10.2174/2212798406666140825120623] [PMID:  25176345]

[16]
Aggarwal V, Tuli HS, Thakral F, et al. Molecular mechanisms of action of hesperidin in cancer: Recent trends and advancements. Exp Biol Med  2020; 245(5): 486-97.
 [http://dx.doi.org/10.1177/1535370220903671] [PMID:  32050794]

[17]
Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice-Evans C. Interaction between flavonoids and the blood-brain barrier: In vitro studies. J Neurochem  2003; 85(1): 180-92.
 [http://dx.doi.org/10.1046/j.1471-4159.2003.01652.x] [PMID:  12641740]

[18]
Parhiz H, Roohbakhsh A, Soltani F, Rezaee R, Iranshahi M. Antioxidant and anti-inflammatory properties of the citrus flavonoids hesperidin and hesperetin: An updated review of their molecular mechanisms and experimental models. Phytother Res  2015; 29(3): 323-31.
 [http://dx.doi.org/10.1002/ptr.5256] [PMID:  25394264]

[19]
Roohbakhsh A, Parhiz H, Soltani F, Rezaee R, Iranshahi M. Molecular mechanisms behind the biological effects of hesperidin and hesperetin for the prevention of cancer and cardiovascular diseases. Life Sci  2015; 124: 64-74.
 [http://dx.doi.org/10.1016/j.lfs.2014.12.030] [PMID:  25625242]

[20]
Mesquita E, Monteiro M. Simultaneous HPLC determination of flavonoids and phenolic acids profile in Pêra-Rio orange juice. Food Res Int  2018; 106: 54-63.
 [http://dx.doi.org/10.1016/j.foodres.2017.12.025] [PMID:  29579958]

[21]
Shimoda K, Hamada H, Hamada H. Glycosylation of hesperetin by plant cell cultures. Phytochemistry  2008; 69(5): 1135-40.
 [http://dx.doi.org/10.1016/j.phytochem.2007.11.008] [PMID:  18160083]

[22]
Tejada S, Pinya S, Martorell M, et al. Potential anti-inflammatory effects of hesperidin from the genus citrus. Curr Med Chem  2019; 25(37): 4929-45.
 [http://dx.doi.org/10.2174/0929867324666170718104412] [PMID:  28721824]

[23]
Ramana KVR, Govindarajan VS, Ranganna S, Kefford JF. Citrus fruits-Varieties, chemistry, technology, and quality evaluation. Part I: Varieties, production, handling, and storage. CRC Crit Rev Food Sci Nutr  1981; 15(4): 353-431.
 [http://dx.doi.org/10.1080/10408398109527321] [PMID:  7037309]

[24]
Mitsunaga Y, Takanaga H, Matsuo H, et al. Effect of bioflavonoids on vincristine transport across blood–brain barrier. Eur J Pharmacol  2000; 395(3): 193-201.
 [http://dx.doi.org/10.1016/S0014-2999(00)00180-1] [PMID:  10812049]

[25]
Lev N, Barhum Y, Ben-Zur T, Melamed E, Steiner I, Offen D. Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity. J Mol Neurosci  2013; 50(3): 542-50.
 [http://dx.doi.org/10.1007/s12031-013-9984-9] [PMID:  23536331]

[26]
Shulman JM, De Jager PL, Feany MB. Parkinson’s disease: Genetics and pathogenesis. Annu Rev Pathol  2011; 6(1): 193-222.
 [http://dx.doi.org/10.1146/annurev-pathol-011110-130242] [PMID:  21034221]

[27]
Antunes MS, Goes ATR, Boeira SP, Prigol M, Jesse CR. Protective effect of hesperidin in a model of Parkinson’s disease induced by 6-hydroxydopamine in aged mice. Nutrition  2014; 30(11-12): 1415-22.
 [http://dx.doi.org/10.1016/j.nut.2014.03.024] [PMID:  25280422]

[28]
Poetini MR, Araujo SM, Trindade de Paula M, et al. Hesperidin attenuates iron-induced oxidative damage and dopamine depletion in Drosophila melanogaster model of Parkinson’s disease. Chem Biol Interact  2018; 279: 177-86.
 [http://dx.doi.org/10.1016/j.cbi.2017.11.018] [PMID:  29191452]

[29]
Kesh S, Kannan RR, Sivaji K, Balakrishnan A. Hesperidin downregulates kinases lrrk2 and gsk3β in a 6-OHDA induced Parkinson’s disease model. Neurosci Lett  2021; 740: 135426.
 [http://dx.doi.org/10.1016/j.neulet.2020.135426] [PMID:  33075420]

[30]
Antunes MS, Cattelan Souza L, Ladd FVL, et al. Hesperidin ameliorates anxiety-depressive-like behavior in 6-ohda model of parkinson’s disease by regulating striatal cytokine and neurotrophic factors levels and dopaminergic innervation loss in the striatum of mice. Mol Neurobiol  2020; 57(7): 3027-41.
 [http://dx.doi.org/10.1007/s12035-020-01940-3] [PMID:  32458386]

[31]
Tamilselvam K, Braidy N, Manivasagam T, et al. Neuroprotective effects of hesperidin, a plant flavanone, on rotenone-induced oxidative stress and apoptosis in a cellular model for Parkinson’s disease. Oxid Med Cell Longev  2013; 2013: 1-11.
 [http://dx.doi.org/10.1155/2013/102741] [PMID:  24205431]

[32]
Cummings J. New approaches to symptomatic treatments for Alzheimer’s disease. Mol Neurodegener  2021; 16(1): 2.
 [http://dx.doi.org/10.1186/s13024-021-00424-9] [PMID:  33441154]

[33]
Wang D, Liu L, Zhu X, Wu W, Wang Y. Hesperidin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress in a mouse model of Alzheimer’s disease. Cell Mol Neurobiol  2014; 34(8): 1209-21.
 [http://dx.doi.org/10.1007/s10571-014-0098-x] [PMID:  25135708]

[34]
Thenmozhi AJ, Raja TRW, Janakiraman U, Manivasagam T. Neuroprotective effect of hesperidin on aluminium chloride induced Alzheimer’s disease in Wistar rats. Neurochem Res  2015; 40(4): 767-76.
 [http://dx.doi.org/10.1007/s11064-015-1525-1] [PMID:  25630717]

[35]
Li C, Zug C, Qu H, Schluesener H, Zhang Z. Hesperidin ameliorates behavioral impairments and neuropathology of transgenic APP/PS1 mice. Behav Brain Res  2015; 281: 32-42.
 [http://dx.doi.org/10.1016/j.bbr.2014.12.012] [PMID:  25510196]

[36]
Lee D, Kim N, Jeon SH, et al. Hesperidin improves memory function by enhancing neurogenesis in a mouse model of alzheimer’s disease. Nutrients  2022; 14(15): 3125.
 [http://dx.doi.org/10.3390/nu14153125] [PMID:  35956303]

[37]
Correale J, Gaitán MI, Ysrraelit MC, Fiol MP. Progressive multiple sclerosis: From pathogenic mechanisms to treatment. Brain  2017; 140(3): 527-46.
 [PMID:  27794524]

[38]
Farzaei MH, Shahpiri Z, Bahramsoltani R. nia MM, Najafi F, Rahimi R. Efficacy and tolerability of phytomedicines in multiple sclerosis patients: A review. CNS Drugs  2017; 31(10): 867-89.
 [http://dx.doi.org/10.1007/s40263-017-0466-4] [PMID:  28948486]

[39]
Ciftci O, Ozcan C, Kamisli O, Cetin A, Basak N, Aytac B. Hesperidin, a citrus flavonoid, has the ameliorative effects against experimental autoimmune encephalomyelitis (EAE) in a C57BL/J6 mouse model. Neurochem Res  2015; 40(6): 1111-20.
 [http://dx.doi.org/10.1007/s11064-015-1571-8] [PMID:  25859982]

[40]
Haghmorad D, Mahmoudi MB, Salehipour Z, et al. Hesperidin ameliorates immunological outcome and reduces neuroinflammation in the mouse model of multiple sclerosis. J Neuroimmunol  2017; 302: 23-33.
 [http://dx.doi.org/10.1016/j.jneuroim.2016.11.009] [PMID:  27912911]

[41]
Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology  2005; 65(5): 745-7.
 [http://dx.doi.org/10.1212/01.wnl.0000174432.87383.87] [PMID:  16157910]

[42]
Kumar P, Kumar A. Protective effect of hesperidin and naringin against 3-nitropropionic acid induced Huntington’s like symptoms in rats: Possible role of nitric oxide. Behav Brain Res  2010; 206(1): 38-46.
 [http://dx.doi.org/10.1016/j.bbr.2009.08.028] [PMID:  19716383]

[43]
Kumar A, Chaudhary T, Mishra J. Minocycline modulates neuroprotective effect of hesperidin against quinolinic acid induced Huntington’s disease like symptoms in rats: Behavioral, biochemical, cellular and histological evidences. Eur J Pharmacol  2013; 720(1-3): 16-28.
 [http://dx.doi.org/10.1016/j.ejphar.2013.10.057] [PMID:  24211676]

[44]
Fakhoury M. Spinal cord injury: Overview of experimental approaches used to restore locomotor activity. Rev Neurosci  2015; 26(4): 397-405.
 [http://dx.doi.org/10.1515/revneuro-2015-0001] [PMID:  25870961]

[45]
Jorge A, Taylor T, Agarwal N, Hamilton DK. Current agents and related therapeutic targets for inflammation after acute traumatic spinal cord injury. World Neurosurg  2019; 132: 138-47.
 [http://dx.doi.org/10.1016/j.wneu.2019.08.108] [PMID:  31470153]

[46]
Heo SD, Kim J, Choi Y, Ekanayake P, Ahn M, Shin T. Hesperidin improves motor disability in rat spinal cord injury through anti-inflammatory and antioxidant mechanism via Nrf-2/HO-1 pathway. Neurosci Lett  2020; 715: 134619.
 [http://dx.doi.org/10.1016/j.neulet.2019.134619] [PMID:  31715292]

[47]
Yurtal Z, Altug ME, Unsaldi E, Secinti IE, Kucukgul A. Investigation of neuroprotective and therapeutic effect of hesperidin in experimental spinal cord injury. Turk Neurosurg  2020; 30(6): 899-906.
 [http://dx.doi.org/10.5137/1019-5149.JTN.29611-20.2] [PMID:  33216334]

[48]
Gaur V, Kumar A. Hesperidin pre-treatment attenuates NO-mediated cerebral ischemic reperfusion injury and memory dysfunction. Pharmacol Rep  2010; 62(4): 635-48.
 [http://dx.doi.org/10.1016/S1734-1140(10)70321-2] [PMID:  20885004]

[49]
Oztanir MN, Ciftci O, Cetin A, Aladag MA. Hesperidin attenuates oxidative and neuronal damage caused by global cerebral ischemia/reperfusion in a C57BL/J6 mouse model. Neurol Sci  2014; 35(9): 1393-9.
 [http://dx.doi.org/10.1007/s10072-014-1725-5] [PMID:  24676696]

[50]
Anovadiya AP, Sanmukhani JJ, Tripathi CB. Epilepsy: Novel therapeutic targets. J Pharmacol Pharmacother  2012; 3(2): 112-7.
 [PMID:  22629084]

[51]
Kumar A, Lalitha S, Mishra J. Hesperidin potentiates the neuroprotective effects of diazepam and gabapentin against pentylenetetrazole-induced convulsions in mice: Possible behavioral, biochemical and mitochondrial alterations. Indian J Pharmacol  2014; 46(3): 309-15.
 [http://dx.doi.org/10.4103/0253-7613.132180] [PMID:  24987179]

[52]
Kumar A, Lalitha S, Mishra J. Possible nitric oxide mechanism in the protective effect of hesperidin against pentylenetetrazole (PTZ)-induced kindling and associated cognitive dysfunction in mice. Epilepsy Behav  2013; 29(1): 103-11.
 [http://dx.doi.org/10.1016/j.yebeh.2013.06.007] [PMID:  23939034]

[53]
Costigan M, Scholz J, Woolf CJ. Neuropathic pain: A maladaptive response of the nervous system to damage. Annu Rev Neurosci  2009; 32(1): 1-32.
 [http://dx.doi.org/10.1146/annurev.neuro.051508.135531] [PMID:  19400724]

[54]
Tao J, Liu L, Fan Y, et al. Role of hesperidin in P2X3 receptor-mediated neuropathic pain in the dorsal root ganglia. Int J Neurosci  2019; 129(8): 784-93.
 [http://dx.doi.org/10.1080/00207454.2019.1567512] [PMID:  30621504]

[55]
Carballo-Villalobos AI, González-Trujano ME, Alvarado-Vázquez N, López-Muñoz FJ. Pro-inflammatory cytokines involvement in the hesperidin antihyperalgesic effects at peripheral and central levels in a neuropathic pain model. Inflammopharmacology  2017; 25(2): 265-9.
 [http://dx.doi.org/10.1007/s10787-017-0326-3] [PMID:  28265836]

[56]
Semis HS, Kandemir FM, Kaynar O, Dogan T, Arikan SM. The protective effects of hesperidin against paclitaxel-induced peripheral neuropathy in rats. Life Sci  2021; 287: 120104.
 [http://dx.doi.org/10.1016/j.lfs.2021.120104] [PMID:  34743946]

[57]
Visnagri A, Kandhare AD, Chakravarty S, Ghosh P, Bodhankar SL. Hesperidin, a flavanoglycone attenuates experimental diabetic neuropathy via modulation of cellular and biochemical marker to improve nerve functions. Pharm Biol  2014; 52(7): 814-28.
 [http://dx.doi.org/10.3109/13880209.2013.870584] [PMID:  24559476]

[58]
Cuijpers P, Quero S, Dowrick C, Arroll B. Psychological treatment of depression in primary care: recent developments. Curr Psychiatry Rep  2019; 21(12): 129.
 [http://dx.doi.org/10.1007/s11920-019-1117-x] [PMID:  31760505]

[59]
Kosari-Nasab M, Shokouhi G, Ghorbanihaghjo A, Abbasi MM, Salari AA. Hesperidin attenuates depression-related symptoms in mice with mild traumatic brain injury. Life Sci  2018; 213: 198-205.
 [http://dx.doi.org/10.1016/j.lfs.2018.10.040] [PMID:  30352242]

[60]
Zhu X, Liu H, Liu Y, et al. The antidepressant-like effects of hesperidin in streptozotocin-induced diabetic rats by activating Nrf2/ARE/Glyoxalase 1 pathway. Front Pharmacol  2020; 11: 1325.
 [http://dx.doi.org/10.3389/fphar.2020.01325]

[61]
Manach C, Morand C, Gil-Izquierdo A, Bouteloup-Demange C, Rémésy C. Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur J Clin Nutr  2003; 57(2): 235-42.
 [http://dx.doi.org/10.1038/sj.ejcn.1601547] [PMID:  12571654]

[62]
Ávila-Gálvez MÁ, Giménez-Bastida JA, González-Sarrías A, Espín JC. New insights into the metabolism of the flavanones eriocitrin and hesperidin: A comparative human pharmacokinetic study. Antioxidants  2021; 10(3): 435.
 [http://dx.doi.org/10.3390/antiox10030435] [PMID:  33799874]

[63]
Khan MK. Zill-E-Huma, Dangles O. A comprehensive review on flavanones, the major citrus polyphenols. J Food Compos Anal  2014; 33(1): 85-104.
 [http://dx.doi.org/10.1016/j.jfca.2013.11.004]

[64]
Kuntić V, Brborić J, Holclajtner-Antunović I, Uskoković-Marković S. Evaluating the bioactive effects of flavonoid hesperidin: A new literature data survey. Vojnosanit Pregl  2014; 71(1): 60-5.
 [http://dx.doi.org/10.2298/VSP1401060K] [PMID:  24516992]

[65]
Dimpfel W. Different anticonvulsive effects of hesperidin and its aglycone hesperetin on electrical activity in the rat hippocampus in-vitro. J Pharm Pharmacol  2010; 58(3): 375-9.
 [http://dx.doi.org/10.1211/jpp.58.3.0012] [PMID:  16536905]

[66]
Zhu X, Liu H, Deng Z, Yan C, Liu Y, Yin X. Hesperidin exerts anxiolytic-like effects in rats with streptozotocin-induced diabetes via PKA/CREB signaling. Curr Mol Pharmacol  2022; 15.
 [http://dx.doi.org/10.2174/1573413718666220314140848] [PMID:  35289260]

[67]
Justin Thenmozhi A, William Raja TR, Manivasagam T, Janakiraman U, Essa MM. Hesperidin ameliorates cognitive dysfunction, oxidative stress and apoptosis against aluminium chloride induced rat model of Alzheimer’s disease. Nutr Neurosci  2017; 20(6): 360-8.
 [http://dx.doi.org/10.1080/1028415X.2016.1144846] [PMID:  26878879]

[68]
Lee B, Choi GM, Sur B. Antidepressant-like effects of hesperidin in animal model of post-traumatic stress disorder. Chin J Integr Med  2021; 27(1): 39-46.
 [http://dx.doi.org/10.1007/s11655-020-2724-4] [PMID:  32445019]

[69]
Wang T, Zheng L, Zhang W. Hesperidin alleviates bupivacaine anesthesia‐induced neurotoxicity in SH‐SY5Y cells by regulating apoptosis and oxidative damage. J Biochem Mol Toxicol  2021; 35(7): e22787.
 [http://dx.doi.org/10.1002/jbt.22787] [PMID:  33830595]

Rights & Permissions Print Cite

Article Metrics

39

2

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1566524023666230320144722	Print ISSN 1566-5240
Publisher Name Bentham Science Publisher	Online ISSN 1875-5666

Current Molecular Medicine

Neuroprotective Potential of Hesperidin as Therapeutic Agent in the Treatment of Brain Disorders: Preclinical Evidence-based Review

Abstract

Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders

Current Molecular Medicine

Neuroprotective Potential of Hesperidin as Therapeutic Agent in the Treatment of Brain Disorders: Preclinical Evidence-based Review

Abstract

Call for Papers in Thematic Issues

Molecular and Cellular Mechanisms in Vertigo / Vestibular Disorders

Related Journals

Related Books

Related Articles